ISO
22716 certified facility
FDA
Registered establishment
cGMP
21 CFR Title 21 §700
OTC
Authorized production
Manufacturing partner
CoValence Laboratories

Island Kinetics, Inc. dba CoValence Laboratories

All SkinTech formula production is conducted exclusively at CoValence Laboratories in Chandler, Arizona. CoValence is an ISO 22716-certified, FDA-registered contract cosmetic and OTC pharmaceutical manufacturer operating under US cGMP standards.

The Quality Agreement between EffectsRx, LLC and CoValence Laboratories, executed April 17, 2017, governs all aspects of the manufacturing relationship including raw material qualification, batch testing, CoA issuance, complaint handling, and recall protocols.

Facility address 460 South Benson Lane, Suite 1-3, Chandler, AZ 85224
NOC Labeler Code 66915
Labeler Code 959735002
FDA Establishment Reg. No. 2032432
FDA inspection August 29 – September 2, 2016
Quality Agreement executed April 17, 2017
ISO 22716 cert issued October 16, 2017
Certification

ISO 22716 — Cosmetics Good Manufacturing Practice

ISO 22716 is the international standard for Good Manufacturing Practices in cosmetic production. It defines requirements for the production, control, storage, and shipment of cosmetic products — covering personnel, premises, equipment, raw materials, production, finished products, quality control, waste management, and subcontracting.

ISO 22716 certification is voluntary in the US but is the recognized international benchmark for serious cosmetic manufacturing. It requires a successful third-party audit of the manufacturing facility against the full standard. CoValence's certification was issued following audit on October 16, 2017, and was valid through November 2018 with ongoing renewal.

ISO 22716 certification scope
  • All materials undergo strictest Quality Control per ISO 22716 standard
  • Manufacturing to Cosmetic cGMP as outlined in US Code of Federal Regulations, CFR Title 21, Section 700
  • All batches tested at multiple stages: correct compounding, packaging, and labeling verification
  • FDA-registered as authorized to produce OTC registered products, reviewed during FDA audits
Quality management system

What the Quality Agreement covers.

The Quality Agreement between EffectsRx, LLC and CoValence Laboratories (executed April 17, 2017) formally allocates quality responsibilities between manufacturer and client. Key provisions:

Raw materials

Material qualification

CoValence is responsible for testing and release of all raw materials. Client-supplied actives (including the pharmaceutical-grade PBN spin trap compound) are held to the same testing requirements as CoValence-stocked materials, including micro testing.

Production

Batch testing & release

CoValence is responsible for testing and release of all finished goods. Products are tested at multiple production stages. Batch records are maintained. Certificates of Analysis (CoA) are issued on request for any produced batch.

Packaging

Component qualification

10% incoming inspection of approved packaging components on initial receipt. Full quality and quantity check of all packaging during the fill process. Compatibility evaluated through stability testing in actual marketed packaging.

Facility

Facility standards

CoValence ensures that facilities, equipment, personnel, training, procedures, and products remain compliant with the applicable quality programs. Audits permitted with 7 days' notice under a current NDA.

Change control

Change notifications

CoValence reviews and submits all change control documentation when changes affect form, function, or labeling of a product. EffectsRx, LLC is notified of any such change.

Post-market

Complaints & recalls

All complaints recorded and investigated per CoValence's Customer Complaint SOPs. Recall decisions are made jointly, with both parties involved in end-user notification and disposition of returned or unused product.

Product-level testing

Testing conducted on SkinTech formulas.

Accelerated Stability Test — ERX0-5001 Night Cream (glass jar)
T090517C · October 18, 2017 – January 9, 2018 · CoValence QA/QC
Pass — 24-month projected shelf life
Accelerated Stability Test — ERX0-5001 Night Cream (30mL pump bottle)
T090517C Batch 4 · CoValence QA/QC
Pass — 24-month projected shelf life
Freeze/Thaw Stability — ERX0-5001
3 cycles at −20°C / 25°C · CoValence QA/QC
Completed
Stress Test — ERX0-5001
Elevated temperature (45°C) · CoValence QA/QC
Completed
Microbial Challenge Test — ERX0-5000 Morning Cream
5–6 weeks · water-containing formula · preservation system qualification
Pass
Microbial Challenge Test — ERX0-5001 Night Cream
5–6 weeks · water-containing formula · preservation system qualification
Pass
RIPT (Repeat Insult Patch Test) — ERX0-5000, ERX0-5001, ERX0-5002
8–10 weeks · primary irritation and sensitization evaluation · all commercial variants
Pass
Stability Test — ERX0-5000 Morning Cream variants
Women's scent, Men's scent · CoValence QA/QC · 12-week protocol
Completed

Documentation available on request

Certificates of Analysis, full stability test reports, RIPT results, the Quality Agreement, ISO 22716 certificate, and cGMP Quality Management Certificate are available to authorized parties on request. Contact EffectsRx, LLC directly.

Legal entity

EffectsRx, LLC

EffectsRx, LLC is the legal entity under which all SkinTech formulas were developed, and under which the CoValence quality and manufacturing agreements are held. Lori Howard is the founding member and registered agent.

All downstream brands in the SkinTech family license or operate under the EffectsRx, LLC formulation platform. The intellectual property in the formulas — the concentration ratios, ingredient interactions, and the Spin Trap System™ as applied to this formula class — remains with EffectsRx, LLC.

Entity EffectsRx, LLC
Founder / Registered agent Lori Howard
Established 2015
Website skintechresearch.com
Formulas ERX0-5000, ERX0-5001, ERX0-5002